Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...89101112131415161718...208209»
  • ||||||||||  AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Neoadjuvant Adebrelimab plus SOX and Nab-Pac in Resectable LA-G/GEJ Adenocarcinoma: A Single-arm, Phase II Trial (Poster venue | Pacifico Yokohama Exhibition Hall D) -  Mar 2, 2026 - Abstract #JSMO2026JSMO_1550;    
    P3
    The KEYNOTE-585 study reported that the neoadjuvant and adjuvant pembrolizumab plus cisplatin-based chemotherapy group achieved a higher pathological complete response rate than the placebo plus cisplatin-based chemotherapy group...We explored that neoadjuvant adebrelimab(an anti-PD-L1 antibody) plus SOX (S-1 and oxaliplatin) and nab-paclitaxel would improve the pathological complete response rate of patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma...Secondary research endpoints include: major pathologic response, objective response rate, R0 resection rate, disease-free survival, overall survival, and safety. Exploratory endpoints include: the relationship between survival and ctDNA post-preoperative treatment; survival and MRD post-curative surgery; and the expression of peripheral blood T lymphocyte subsets and prognosis.
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Neoadjuvant Adebrelimab + SOX + Nab-Pac in Resectable LA-G/GEJ Adenocarcinoma: Preliminary data from a Phase II Trial (Room 9 | Pacifico Yokohama North 3F G314+G315) -  Mar 2, 2026 - Abstract #JSMO2026JSMO_828;    
    [Methods] All eligible patients will receive neoadjuvant treatment consisting of adebrelimab, SOX (S-1 plus oxaliplatin), and nab-paclitaxel every 21 days for four cycles...Pathological results were available for 7 patients, among whom 2 achieved pCR (28.6%), and 1 achieved MPR (42.9%). [Conclusions] Neoadjuvant adebrelimab combined with SOX and nab-paclitaxel has shown promising preliminary efficacy in patients with resectable LA-G/GEJ adenocarcinoma.
  • ||||||||||   Recent updates in the systemic therapy for advanced HCC (Room 4 | Pacifico Yokohama North 1F G5) -  Mar 2, 2026 - Abstract #JSMO2026JSMO_651;    
    The IMbrave150 trial established atezolizumab plus bevacizumab as the first FDA-approved immune-based combination therapy, demonstrating superior OS and PFS over sorafenib...More recently, the CARES-310 and CheckMate 9DW trials have expanded the ICI landscape, with camrelizumab-rivoceranib and nivolumab-ipilimumab, respectively, demonstrating efficacy in the first-line setting...In conclusion, the management of advanced HCC has entered a new era of immunotherapy and targeted therapy combinations. Personalized treatment selection, expert consensus, and real-world data will be key to optimizing outcomes in this evolving field.
  • ||||||||||  AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Enrollment open, Trial primary completion date:  Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC. (clinicaltrials.gov) -  Feb 28, 2026   
    P2,  N=60, Recruiting, 
    N=82 --> 160 | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026 Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2025 --> Jun 2026
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Enrollment open:  Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib (clinicaltrials.gov) -  Feb 28, 2026   
    P2,  N=48, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2025 --> Jun 2026 Not yet recruiting --> Recruiting
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, cisplatin / Generic mfg.
    Preclinical, Journal:  Antitumor Effects of Apatinib on Tongue Cancer in Patient-Derived Xenograft Models. (Pubmed Central) -  Feb 26, 2026   
    These findings support its potential as a targeted therapy for tongue cancer and highlight the utility of PDX models for preclinical drug evaluation. Further studies with larger cohorts are warranted to validate these results.
  • ||||||||||  Early rapid progression after first-line CDK4/6 inhibitor (Exhibition Area) -  Feb 25, 2026 - Abstract #ESMOBC2026ESMO_BC_618;    
    Among 341 patients, At follow-up, 74 deaths occurred.23.8% experienced early rapid progression. In this single-center real-world study, Nearly one quarter of patients experienced early rapid progression after first-line CDK4/6 inhibitor
  • ||||||||||  remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
    Enrollment open, Phase classification, Enrollment change:  A Trial of Remimazolam for Intraoperative Sedation in Pediatric and Adolescent Patients (clinicaltrials.gov) -  Feb 18, 2026   
    P2/3,  N=240, Recruiting, 
    These findings suggest that immunotherapy may represent a potential treatment approach for high PD-L1 expression of METex14 NSCLC patients, warranting further investigation in larger cohorts. Not yet recruiting --> Recruiting | Phase classification: P2 --> P2/3 | N=138 --> 240
  • ||||||||||  oxaliplatin / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group, albumin-bound paclitaxel / Generic mfg.
    Journal:  Alteration of tumor characteristics following neoadjuvant treatment in gastric adenocarcinoma: a case report. (Pubmed Central) -  Feb 16, 2026   
    Postoperative recovery was uneventful, and the patient was discharged in improved condition. Notably, postoperative pathological analysis revealed a neuroendocrine tumor, demonstrating an alteration in tumor histology after neoadjuvant therapy for gastric cancer (GC).
  • ||||||||||  cyclophosphamide / Generic mfg., Hengqu (hetrombopag) / Jiangsu Hengrui Pharma, cyclosporine / Generic mfg.
    Journal:  Low-dose cyclophosphamide combined with standard immunosuppressive therapy improves early response rates in severe aplastic anemia. (Pubmed Central) -  Feb 16, 2026   
    Thrombopoietin receptor agonists combined with anti-thymocyte globulin (ATG) and cyclosporine (CsA) are the standard immunosuppressive therapy (IST) for severe/very severe aplastic anemia (SAA/VSAA)...Newly diagnosed SAA/VSAA patients received a combination treatment as follows: porcine ATG at 25 mg/kg/day from days 1 to 5, CsA at 3-5 mg/kg/day continuously, hetrombopag at 15 mg/day starting from day 1 and continued for 6 months, low-dose CTX at 20 mg/kg/day on days 29-30 and days 43-44...Infectious events occurred in 60.5% (26/43) of patients within the first 3 months of treatment, while no mortality observed during this period. Low-dose CTX combined with standard IST appears to improve the early response rate in SAA/VSAA patients with manageable toxicity.
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
    Enrollment open, Enrollment change, Trial completion date, Trial primary completion date:  SHR-A1811-Ib/II-205: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer (clinicaltrials.gov) -  Feb 13, 2026   
    P2,  N=258, Recruiting, 
    Neoadjuvant chemoimmunotherapy shows high rates of pCR for ER-low BC, resembling triple-negative BC, with safety data indicating fewer severe complications than observed in pivotal trials. Active, not recruiting --> Recruiting | N=76 --> 258 | Trial completion date: Jul 2026 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Dec 2027
  • ||||||||||  Review, Journal:  Cyclin-Dependent 4/6 Kinase Inhibitors for Treatment of HER2-Positive Breast Cancer: 2026 Update. (Pubmed Central) -  Feb 13, 2026   
    Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i; palbociclib, ribociclib, abemaciclib, dalpiciclib) combined with endocrine therapy (ET) were a major advance in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) worldwide...However, clinical development of CDK4/6i in HER2+ MBC slowed, given the advent of highly effective tyrosine-kinase inhibitors (TKIs) (i.e., tucatinib) and antibody-drug conjugates (ADCs) (i.e., trastuzumab deruxtecan), which currently dominate the treatment armamentarium...Subsequently, the phase III PATINA trial (which included patients with 1L HR+HER2+ MBC, treated with palbociclib vs. placebo with maintenance ET+ H[P]) noted a striking PFS improvement of >15 months in the palbociclib arm, renewing interest in CDK4/6i-based treatments for HR+HER2+ MBC. Herein, we review the development of CDK4/6i in HER2+ BC, discussing current challenges and potential future directions.
  • ||||||||||  Retrospective data, Review, Journal:  Multi-Targeted TKIs in Patients with Advanced Ewing Sarcoma: A Systematic Review and Single-Arm Meta-Analysis. (Pubmed Central) -  Feb 13, 2026   
    The following TKIs were evaluated: cabozantinib, regorafenib, apatinib, anlotinib, sorafenib, lenvatinib, sunitinib, fruquintinib, and imatinib...Efficacy was consistently seen in both clinical trials and real-world studies. Nonetheless, there are important differences in study design and population that may limit our interpretation of efficacy and toxicity findings.
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma
    Journal:  CD24 overexpression confers resistance to Pyrotinib through inhibiting autophagy in patients with HER2-positive breast cancer. (Pubmed Central) -  Feb 12, 2026   
    Furthermore, CD24 knockdown reduced its expression level by promoting the ubiquitination modification of epidermal growth factor receptor (EGFR), and significantly inhibited its downstream AKT/mTOR signaling pathway. By interacting with EGFR and modulating the mTOR pathway, CD24 acted as a critical regulator of autophagic cell death, thereby enhancing the sensitivity of HER2+ BC cells and reversing Pyrotinib resistance.